secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lakewood-Amedex Biotherapeutics Inc. (LABT)
CIK:        0002079272
Form:       8-K
Filed at:   2026-06-17T15:40:39+00:00
Accession:  0001213900-26-069512
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lakewood-Amedex announces 1-for-10 reverse stock split effective June 19, 2026
------------------------------------------------------------------------------

- Reverse split ratio: 1-for-10; effective at 4:01 p.m. ET on June 19, 2026; trading starts split-adjusted on Nasdaq June 22.
- Outstanding shares reduced from ~17,506,577 to ~1,750,789; fractional shares rounded up to next whole share.
- Authorized shares reduced proportionately to 12,500,000; new CUSIP 51255A201 assigned; ticker LABT unchanged.
- Board unanimously approved the split on June 1, 2026; adjustments made to equity awards, warrants, and preferred stock.
- No stated reason for the split; typical use is to regain Nasdaq minimum bid price compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/0001213900-26-069512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/ea0294845-8k_lakewood.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-069512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer